



CALIFORNIA NEUROLOGY SOCIETY

“NeuroRheumatology Crossroads”

October 31 - November 3, 2024

Planner/Faculty Disclosure Statement

Planner Name	Relevant Financial Relationship	Company	COI?	Explain how Resolved
CME CONSULTANTS' REVIEWERS				
William Choctaw, MD, JD	None	N/A	N/A	N/A
Harold D. Damuth, Jr., MD	None	N/A	N/A	N/A
Lester Holstein, MD	None	N/A	N/A	N/A
Michael J. Marchiano, MD	None	N/A	N/A	N/A
CME CONSULTANTS' STAFF				
Nancy Williams	None	N/A	N/A	N/A
Priscilla Graham	None	N/A	N/A	N/A
CNS PLANNERS				
Virginia Ho	None	N/A	N/A	N/A
Stella Legarda MD	None	N/A	N/A	N/A
Johanna Rosenthal, MD	None	N/A	N/A	N/A
George Sarka, MD, DrPH, MPH	None	N/A	N/A	N/A
Robert Weinmann MD	None	N/A	N/A	N/A
Robyn Young MD	None	N/A	N/A	N/A
FACULTY				
Chay Bae, DO	None	N/A	N/A	N/A
Jeff M. Bronstein, MD, PhD	None	N/A	N/A	N/A
Steve Cattolica	None	N/A	N/A	N/A
Thomas C. Cesario, MD	None	N/A	N/A	N/A
Robert I. Fox, MD, PhD, FACP	None	N/A	N/A	N/A
Mariko Ishimori, MD	None	N/A	N/A	N/A
Mary C. Karalius, MD	None	N/A	N/A	N/A
Tanaz A. Kermani, MD, MS, FACP, FACR	None	N/A	N/A	N/A
Stella Legarda, MD	None	N/A	N/A	N/A
Christopher B. Lock, MBBS, PhD	Speakers Bureau	Amgen	Yes	*Peer review.
Shalini Mahajan, MD	None	N/A	N/A	N/A
Mark J. Morrow, MD	None	N/A	N/A	N/A
Rodrigo Rodriguez, Jr., MD	None	N/A	N/A	N/A
Johanna Rosenthal, MD	None	N/A	N/A	N/A
George Sarka, MD, DrPH	None	N/A	N/A	N/A
Perry Shieh, MD, PhD	Speaker	argenx SE; CSL Behring; Grifols	Yes	*Peer review.
Stuart Silverman, MD, FACP, FACR	Grant Recipient and Consultant	Amgen	Yes	*Peer review.
	Grant Recipient	Lilly		
	Speaker	CellTrans		
R Swamy Venuturupalli, MD, FACR	Study site for clinical trial	Argenx SE; Johnson & Johnson Innovative Medicine (Janssen)	Yes	*Peer review.

		Pharmaceuticals); Navidea Biopharmaceuticals, Inc.		
Daniel J. Wallace, MD, FACP, MACR	Consultant/ Speaker	Amgen; Arunia Pharmaceuticals ; AstraZeneca; Exagen Inc.; GSK; Lilly; EMD Serono (Merck KGaA)	Yes	*Peer review.
Robert Weinmann, MD	None	N/A	N/A	N/A
Michael R. Wilson, MD, MAS, FAAN, FANA	Research Grant	Genentech (Roche Group); Kyverna Therapeutics	Yes	*Peer review.
	Research Grant	Novartis		
	Co-Founder and Board of Directors	Delve Bio	No	Delve Bio does not have any products/services with FDA approval, nor which are in the PMA process. It is therefore NOT an ineligible company.
Dean M. Wingerchuk, MD	Consulting or Advisory Board	Alexion Pharmaceuticals; Amgen; AstraZeneca; Bristol Myer Squib; EMD Serono; Genentech; Horizon Pharmaceuticals; Kyenta Therapeutics, Inc.; Merck KGaA; Novartis; Reistone Biopharma; Imcyse; Roche Pharmaceuticals; TTY Biopharm; UCB Pharma	Yes	*Peer review.
	Clinical Trial Adjudication Committee	UCB Pharma		
	Data Safety Monitoring Committee	Abcuro; Alexion		
	Consulting or Advisory Board	Guthy Jackson Charitable Foundation;	No	N/A

*Presentation materials have been peer reviewed and found to be fair, balanced, evidence-based, and free from commercial bias.

COMMERCIAL SUPPORT STATEMENT

There is no commercial support for this activity.